Earlier this year, the administration’s proposal to sharply cut National Institutes of Health funding prompted swift bipartisan opposition. Critics argue that undermining medical research—particularly in fields like Alzheimer’s and obesity—puts urgently needed treatments at risk and worsens the potential impact of MFN pricing on drug innovation.